UK markets close in 3 hours 36 minutes

FibroGen, Inc. (0IL8.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
52.55-0.14 (-0.26%)
As of 2:33PM GMT. Market open.

FibroGen, Inc.

409 Illinois Street
San Francisco, CA 94158
United States
415 978 1200

Full-time employees531

Key executives

NameTitlePayExercisedYear born
Mr. James A. SchoeneckChairman751.63k934.26k1958
Mr. Pat CotroneoChief Financial Officer773.57k3.79M1964
Dr. K. Peony YuExec. Advisor to Chief Exec. Officer926.21k396.02k1962
Dr. Elias KouchakjiSr. VP of Clinical Devel., Drug Safety & Pharmacovigilance863.19k471.6k1956
Ms. Christine L. ChungSr. VP of China Operations701.09k2.39M1968
Mr. Enrique A. ConternoCEO & DirectorN/AN/A1967
Dr. Barry A. BerkowitzFounderN/AN/AN/A
Dr. Michael J. MartinelliSr. VP of Technical Devel.N/AN/AN/A
Dr. Percy Carter M.B.A., Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Karen L. BergmanVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Corporate governance

FibroGen, Inc.’s ISS governance QualityScore as of 2 December 2020 is 5. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.